Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 13/20 | 0.46 |
| ▸ | MMP2 | P08253 | 6/20 | 0.46 |
| ▸ | MMP3 | P08254 | 15/20 | 0.46 |
| ▸ | MMP1 | P03956 | 14/20 | 0.46 |
| ▸ | MMP7 | P09237 | 7/20 | 0.46 |
| ▸ | MMP13 | P45452 | 4/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076042 | 0.92 | CA12 (0.53) | CA12CA1CA2CA9MMP9 | |
| SCHEMBL7389317 | 0.89 | CA12 (0.50) | CA12CA1CA2CA9MMP9 | |
| SCHEMBL6075691 | 0.87 | MMP3 (0.49) | CA12CA1CA2CA9MMP9 | |
| SCHEMBL6075812 | 0.87 | CA12 (0.48) | CA12CA1CA2CA9MMP9 | |
| SCHEMBL6076126 | 0.83 | MMP3 (0.47) | MMP9MMP2MMP3MMP1MMP7 | |
| SCHEMBL6075406 | 0.83 | MMP3 (0.46) | MMP9MMP2MMP3MMP1MMP7 | |
| SCHEMBL6076690 | 0.82 | HCRTR1 (0.47) | CA12CA1CA2CA9MMP9 | |
| SCHEMBL7389321 | 0.81 | CA12 (0.47) | CA12CA1CA2CA9MMP9 | |
| SCHEMBL6076295 | 0.81 | MMP3 (0.51) | MMP9MMP2MMP3MMP1MMP7 | |
| SCHEMBL6075492 | 0.81 | MMP1 (0.45) | CA12CA1CA2CA9MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022690-B2 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | AMGEN INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050159407-A1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | AMGEN INC. | 2005-07-21 | — | — | US | disclosed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-6838454-B2 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | AMGEN INC. (US) | 2005-01-04 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| US-20040029863-A1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | AMGEN INC. | 2004-02-12 | — | — | US | disclosed |
| US-6593351-B2 | 3-Sulfonylamino-c5 to c8-methyleneimino-2-carboxylic acid compound is effective for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases | AMGEN INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1042297-B1 | CARBOXYL ACID SUBSTITUTED HETEROCYCLES AS METALLOPROTEINASE INHIBITORS | AMGEN INC (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020065269-A1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | AMGEN INC. | 2002-05-30 | — | — | US | disclosed |
| US-6335329-B1 | N-SULFONYL-3-AMINOAZEPINE-2-CARBOXYLIC ACID DERIVATIVES; ANTIINFLAMMATORY, ANTICARCINOGENIC, AND ANTIARTHRITIC AGENTS; METALLOPROTEINASE INHIBITORS | AMGEN INC. | 2002-01-01 | — | — | US | disclosed |
| US-6291450-B1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | AMGEN INC. | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029863-A1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | HCAR2, HCAR1, TNF | CA12 452/4885CA1 555/4885CA2 499/4885 |
| US-20020065269-A1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | HCAR2, HCAR1, TNF | CA12 452/4885CA1 555/4885CA2 499/4885 |
| US-20050159407-A1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | HCAR2, HCAR1, TNF | CA12 452/4885CA1 555/4885CA2 499/4885 |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | CA12 4558/4885CA1 3035/4885CA2 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.